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The results of a meta-analysis of 19 clinical trials provide evi-
dence for a beneficial, statistically significant as well as clinically
relevant efficacy of diacerein on pain and the functional status
in patients suffering from hip and knee OA [19]. The number of
patients inluded in this meta-analysis, namley, 1328 diacerein-
treated patients and 1309 patients in the comparator groups
(placebo or NSAID) gives the basis for well founded conclusions
to be drawn from this investigation.
It could be shown that diacerein was superior to placebo and
as effective as NSAIDs with respect to the reduction of pain as
well as to the improvement of function which are considered to
constitute major response criteria in OA during the treatment pe-
riod. As functionality is highly dependent upon pain its reduction
relates directly to the improvement of the functional status.
Considering the pain relief results, one has to keep in mind that
no complete withdrawal of analgesic medication was possible
during the investigations analyzed within this meta-analysis. In
most of the trials, acetaminophen, which can be also seen as an
appropriate treatment of moderate OA, was allowed as additional
medication.
In addition the results of this meta-analysis give a proof for the
carry over effect, SYSADOA are postulated to exert, concerning
pain assessed by VAS.
The most common side effects of diacerein are related to the
gastrointestinal tract like abdominal pain or diarrhoe. Moreover,
change of the urine colouration, pruritus and skin rash occurred
within the clinical trials. All these adverse events were reversible
and not life threatening. In France, over a period of 11 years
(from September 1994 to November 2005) and with more than
14 million prescriptions of DIA, only 9 cases of cardiovascular
adverse events with DIA were spontaneously reported. Patient
tolerability assessments revealed the superiority of placebo over
diacerein with no differences between diacerein and NSAIDs.
Given the meta-analytic results obtained here, a trial powered
to ultimately prove the usefulness of diacerein as a symptom-
modifying or even disease-modifying drug in osteoarthritis can
be expected to give similar results.
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GLUCOSAMINE
Karel Pavelka
Despite several new studies [1,2] several meta-analysis and new
Cochrane analysis, discussion on efficacy of glucosamine in both
symptomatic and structural modification of OA continues.
Why? Firstly, there are general problems with evaluation of drugs
in OA. There is high placebo response, problem with rescue
medication and other therapies. We definitively need better study
designs and outcome measures.
Secondly there is a problem with the drug. Is glucosamine sulfate
equally effective as glucosamine hydrochloride? New studies
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have clearly documented higher bioavailibility of glucosamine
sulfate then of glucosamine hydrochloride.
Thirdly there is need for standardization of radiographic methods
and validation of new methods like MRI for easier and more
precise proof of potential retarding effect of drug on cartilage
degeneration.
Fourthly we need to know more, about exact mechanism of
action of GS. New knowledge of effect of GS on inhibition of the
cytokine intracellular signalling pathway, namely of the activation
of NF – kB is an example of this.
Fifthly there are differences in regulatory aspects of glucosamine
being registered as drug in Europe and nutritient in US that again
complicates situation.
Conclusions: Overall studies support efficacy of glucosamine.
Discrepancies may relate to product variation. NIH study will add
further to current information.
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CHONDROITIN SULPHATE
Beat A. Michel
Background: Chondroitin Sulphate (CS) is widely used through-
out the world for the treatment of osteoarthritis (OA). EULAR
recommendations include CS as a symptomatic slow acting drug
for OA (SYSADOA) in the management of both knee and hip OA
(strength of recommendation according to category 1 evidence).
However, many controversies remain to this date.
Evidence of symptomatic efficacy: Meta-analyses have shown,
that effect sizes regarding the symptomatic efficacy of CS in
published studies are high (reaching 0.8). However, effect sizes
are diminished when only high quality and large trials are con-
sidered. For both pain and functional outcomes effect sizes were
relatively consistent.
Not all studies have found significant symptomatic efficacy.
Whether this finding is based on a floor effect (very low base-
line values), patient selection, large response within the placebo
group or other factors is open to debate.
Structure modifying effect: Two large studies have examined
the structure modifying effect of CS in OA of the knee. Both stud-
ies, one one-center study and one multi-center European study
have found significant differences in the progression of disease
between treated and placebo groups over two years. Both studies
used flexed radiographic views to assess the outcome parame-
ters of joint space narrowing. In both studies automatic reading
of digitized radiographs were used. A further NIH-sponsored
large trial will be analysed within the next months with regard to
structure modification.
Open questions: Many issues regarding the treatment of CS
are still open and need appropriate assessment: Absorption
via the gastrointestinal tract; exact way of action leading to
symptomatic relief and/or structure modification; optimal dosage;
optimal origin of substance; schedule of treatment over time;
efficacy in the treatment of OA of hands and spine.
Conclusion: Overall CS appears to possess symptomatic slow
onset efficacy in OA of the hip and knee, although the effect sizes
may be smaller than suggested by the publications available. Also
current data support structure modifying effects of CS in OA of
the knee. However, much more work is needed to understand
the exact mechanisms of action all the way from the intake of the
substance to the suggested outcomes. The fact, that CS is very
well tolerated, will further stimulate ongoing work in this field.
